Two studies presented at ASCO's annual meeting used ctDNA testing to determine which patient might benefit from anti-EGFR retreatment.

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

Ichnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus ...

Researchers at the Ragon Institute have made a significant discovery about how antibodies can directly enhance the body's ...

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.